Dambkowski Carl sold 5,500 shares of Apogee Therapeutics, Inc. at $78.71 for −$433k on Jun 3, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Medical Officer
Chief Medical Officer
Filed Jun 5, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$432,905Shares × reported price
Shares traded
5,500Common Stock
Price per share
$78.71Reported price. Read footnotes for ranges.
% of reported position traded
2.6%This security and ownership context
Holdings after
205,648Direct
Trade date
Jun 3, 2026Sell
Filed
Jun 5, 2026, 8:00 PM ET3-day reporting delay
Accession
0001104659-26-071076Code S · Transaction 99767
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 211,148 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Jun 3, 2026Option exercise4,125$22.86$94,297.50Trade 99765
Jun 3, 2026Option exercise4,125$0.00$0Trade 99768
3 transaction rows in this filing. Joint filers share the same rows.

APGE price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
APGE · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −3.9%1w ago −11%1d ago −9.5%
Returns since7d +1.6%30d +54%90d180d1y

Footnotes in full

F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. F2: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.